Regeneron Pharmaceuticals Announced New Analyses Of Eylea HD (Aflibercept) Injection 8 Mg And Eylea Injection 2 Mg Will Be Presented At The Annual Meeting Of The European Society Of Retina Specialists
Regeneron Pharmaceuticals Announced New Analyses Of Eylea HD (Aflibercept) Injection 8 Mg And Eylea Injection 2 Mg Will Be Presented At The Annual Meeting Of The European Society Of Retina Specialists
再生元製藥公司宣佈對Eylea HD（阿比欣）注射劑8毫克和Eylea注射劑2毫克的新分析將在歐洲視網膜專家年會上進行展示
Among the presentation highlights are several new post-hoc analyses of the pivotal PULSAR trial for EYLEA HD in wet age-related macular degeneration (wAMD). These include first-time oral presentations of:
演講亮點包括對EYLEA HD在溼性年齡相關性黃斑變性（wAMD）中的關鍵PULSAR試驗的幾項新的事後分析。其中包括以下內容的首次口頭陳述：
- An analysis applying disease activity criteria from the faricimab Phase 3 wAMD trials to EYLEA HD to evaluate the impact on the decision for extended dosing intervals.
- An analysis evaluating the impact of EYLEA HD on sustained fluid control throughout two years of treatment as measured by central retinal thickness and best-corrected visual acuity.
- The safety of EYLEA HD from an analysis evaluating intraocular pressure outcomes through week 96.
- 該分析將法瑞西單抗3期WAMD試驗的疾病活性標準應用於EYLEA HD，以評估延長給藥間隔對決策的影響。
- 該分析評估了EYLEA HD在兩年治療期間對持續液體控制的影響，該分析以視網膜中央厚度和最佳矯正視力來衡量。
- EYLEA HD 的安全性來自對第 96 周眼壓預後進行評估的分析。
資訊熱榜
更新時間